Related Experiment Video
Updated: Aug 25, 2025
12:40
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
15.0K
Advances in RIPK1 kinase inhibitors
Lu Chen1, Xiaoqin Zhang2, Yaqing Ou3
1College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Frontiers in Pharmacology
|October 17, 2022
Summary
Programmed necrosis, regulated by receptor interacting protein 1 (RIPK1), is implicated in various diseases. This review details RIPK1 inhibitors, crucial for developing new therapeutic strategies.
Area of Science:
- Molecular Biology
- Cell Biology
- Biochemistry
Background:
- Programmed necrosis is a regulated cell death pathway.
- Receptor interacting protein 1 (RIPK1) is a key mediator in programmed necrosis.
- RIPK1 dysregulation is linked to diseases like stroke, Alzheimer's, and cancer.
Purpose of the Study:
- To review the structure and biological function of RIPK1.
- To summarize recent advancements in RIPK1 kinase inhibitors.
- To categorize existing RIPK1 inhibitors.
Main Methods:
- Literature review of scientific publications.
- Analysis of structural and functional data of RIPK1.
- Classification of RIPK1 inhibitors based on their mechanisms of action.
Main Results:
- RIPK1 is a critical mediator in programmed necrosis.
- RIPK1 inhibitors are classified into four categories based on their targeting.
- These inhibitors offer potential therapeutic avenues for various diseases.
Conclusions:
- RIPK1 kinase inhibitors represent a promising therapeutic target.
- Further research into RIPK1 inhibitors could lead to novel treatments.
- Understanding RIPK1's role is vital for disease intervention.
Related Concept Videos
01:22PI3K/mTOR/AKT Signaling Pathway
3.8K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.8K
02:34Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
03:03mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
02:15M-Cdk Drives Transition Into Mitosis
5.7K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
01:26Receptor Tyrosine Kinases
13.7K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
13.7K
01:07MAPK Signaling Cascades
5.9K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.9K